Patients with blood cancers like polycythemia vera, a kind of myeloproliferative neoplasm, may benefit in learning more about recent data from ASCO 2025.
Dr. Raajit K. Rampal
Advertisement
Rampal is the director of the Center for Hematologic Malignancies, as well as the director of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center, located in New York.
Articles by Dr. Raajit K. Rampal
Advertisement
Latest Updated Articles
What Patients With Polycythemia Vera Should Know After ASCO 2025Published: June 21st 2025 | Updated:
Advertisement
Advertisement
Trending on CURE
1
An Overview of Pancreatic Neuroendocrine Tumors (PNETs)
2
Osteosarcoma Guide: Stages, Treatment, Side Effects and Patient Journey
3
Kidney Cancer Disparities Persist Among American Indian and Alaskan Native Patients
4
TKIs Take Lead After Immunotherapy in Metastatic Kidney Cancer
5
